Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays.
Acta Pharm Sin B. 2022 Apr;12(4):1636-1651. doi: 10.1016/j.apsb.2021.10.026. Epub 2021 Nov 1.
Acta Pharm Sin B. 2022.
PMID: 34745850
Free PMC article.
Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity.
Ma C, Xia Z, Sacco MD, Hu Y, Townsend JA, Meng X, Choza J, Tan H, Jang J, Gongora MV, Zhang X, Zhang F, Xiang Y, Marty MT, Chen Y, Wang J.
Ma C, et al. Among authors: choza j.
J Am Chem Soc. 2021 Dec 15;143(49):20697-20709. doi: 10.1021/jacs.1c08060. Epub 2021 Dec 3.
J Am Chem Soc. 2021.
PMID: 34860011
Free PMC article.
Item in Clipboard
Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor.
Ma C, Hu Y, Wang Y, Choza J, Wang J.
Ma C, et al. Among authors: choza j.
ACS Infect Dis. 2022 May 13;8(5):1022-1030. doi: 10.1021/acsinfecdis.1c00629. Epub 2022 Apr 11.
ACS Infect Dis. 2022.
PMID: 35404564
Free PMC article.
Item in Clipboard
Cite
Cite